MetaCap

IRulya Therapeutics (IRLA) vs REGENXBIO (RGNX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

REGENXBIO is the larger company by market cap ($473.4 million vs $432.4 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IRLA+17.16%RGNX-33.49%
+22%-10%-42%
Aug 14, 20261 yearNov 20, 2026
IRLA+17.16%RGNX-33.49%
+20%-10%-41%
Aug 10, 20265 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IRLA versus RGNX key metrics
MetricIRLARGNX
Share price$39.88$7.16
Market cap$432.36M$473.44M
1-day change-0.15%-0.28%
YTD return—-50.28%
1-year return—-39.32%
5-year return—-76.87%
EPS (TTM)$-162.79$-3.20
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$170.44M
Revenue growth (YoY)—+104.54%
Net income (latest FY)$-83.98M$-193.88M
Operating margin—-94.58%
Net margin—-113.75%
52-week high$910.00$16.19
52-week low$15.10$5.46
Distance from 52-week high-95.62%-55.78%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+90.90%+198.88%
Average volume63.03K1.39M
Shares outstanding10.84M66.12M
Employees38371
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About IRulya Therapeutics

IRLA stock →

IRulya Therapeutics Inc., a biotechnology company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidate comprises eDSP, which is in Phase 3 for the treatment of rare pediatric neurodegenerative diseases, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in the ATM gene.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 38 employees

About REGENXBIO

RGNX stock →

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees

IRLA vs RGNX FAQ

Which is bigger, IRulya Therapeutics or REGENXBIO?

REGENXBIO (RGNX) is larger, with a market capitalization of $473.44M compared with $432.36M for IRulya Therapeutics (IRLA).

Are IRulya Therapeutics and REGENXBIO in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons